What are the prognostic markers for primary central nervous system lymphoma (PCNSL)?

Updated: Jan 19, 2018
  • Author: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print
Answer

Answer

The prognostic value of serum markers in PCNSL was reported in a prospective study of 45 PCNSLs. [19] Disease status, radiographic appearance, and length of survival correlated with serum levels of YKL-40 and MMP-9. The authors’ main objective was to identify disease severity markers as a treatment guide. YKL-40 is a tissue marker of inflammation related to carcinogenesis, and MMP-9 tissue controls remodeling permeability. YKL-40 and MMP-9 levels were associated with “active disease,” particularly if a longitudinal, steady serum level increment was noted. Consistently low serum levels, on the other hand, were found with “absence of tumor.”

In another study, overexpression of BCL-6 was associated with improved survival (median, 101 months) over that of patients whose tumors that did not express BCL-6 (median, 14.7 months). [20] The search is on for additional prognostic markers.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!